20 March 2019 - - US-based clinical-stage biopharmaceutical company Cold Genesys, Inc has closed a USD 22m Series C preferred stock financing, the company said.

New investors participated in the round, including lead investor, ORI Healthcare Fund L.P., with participation from Perseverance Capital Management.

The financing will accelerate the growth of Cold Genesys' ongoing clinical programs and the continued advancement of its lead oncolytic immunotherapy CG0070, which has completed a Phase 2 study (BOND2) and demonstrated clinical safety and efficacy in over 100 patients to date for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

Cold Genesys is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer.

The company's lead candidate CG0070 has completed an investigation in a Phase 2, single-arm, open-label, multicenter study (BOND2) for patients with NMIBC who failed BCG therapy and refused cystectomy.

In addition, Cold Genesys is exploring the use of CG0070 in combination with immune checkpoint modulators in different solid tumors.

ORI Healthcare Fund L.P. is a USD 200m venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally.

The fund is founded by Simone (Hong Fang) Song, former investment banker and head of China Healthcare at Goldman Sachs.